Allarity Therapeutics, Inc. (ALLR)
| Market Cap | 22.43M -3.5% |
| Revenue (ttm) | 345,000 |
| Net Income | -12.33M |
| EPS | -0.79 |
| Shares Out | 15.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,927 |
| Open | 1.380 |
| Previous Close | 1.380 |
| Day's Range | 1.350 - 1.460 |
| 52-Week Range | 0.769 - 2.060 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About ALLR
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced ... [Read more]
Financial Performance
Financial StatementsNews
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic...
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must...
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Comp...
Allarity to present trial-in-progress poster on Phase 2 stenoparib trial
Allarity (ALLR) Therapeutics announced that it will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June 17-19 in Copenhagen, Denmark. The poster outlines the...
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Principal Investigator Kathleen N. Moore, M.D.
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new i...
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121...
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approv...
Allarity receives notice of allowance from USPTO
Allarity (ALLR) announced that the United States Patent and Trademark Office has issued a notice of allowance for its patent application covering the company’s DRP companion diagnostic specific to ste...
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-...
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, en...
Allarity closes $20M financing for stenoparib advancement
Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company is...
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Str...
Allarity doses first patients in Phase 2 trial of SCLC
Allarity (ALLR) Therapeutics announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investigator-initiated Phase 2 trial for the treatment of relapsed smal...
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enro...
Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide
Allarity (ALLR) Therapeutics announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cel...
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by...
Allarity CEO says 2026 represents an ‘inflection point’
Allarity (ALLR) Therapeutics issued a letter to shareholders from the Company’s CEO, which read, in part, “As we close out 2025, I write to you with both optimism and gratitude.
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (...
Allarity files $50M mixed securities shelf
09:12 EST Allarity (ALLR) files $50M mixed securities shelf
Allarity reports Q3 EPS (19c) vs ($7.71) last year
“The third quarter of 2025 was another milestone period for Allarity (ALLR) as we achieved FDA Fast Track designation for stenoparib in advanced ovarian cancer-an important acknowledgment of the poten...
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trial Advanced DRP ® platform through...
Allarity files to sell 1.56M shares of common stock for holders
17:21 EDT Allarity (ALLR) files to sell 1.56M shares of common stock for holders
Allarity presents new Phase 2 clinical data for Stenoparib
Allarity (ALLR) Therapeutics, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib, a differentiated, dual PARP and WNT pathway inhibitor, announced that Dr Jeremy Graff,...
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily